¿¬¼ö°­ÁÂ
´ëÇѺÎÀÎÁ¾¾çÇÐȸ Chemo-TIP Review Course 2024 : 2024-01-13

´ëÇѺÎÀÎÁ¾¾çÇÐȸ Chemo-TIP Review Course 2024 : 2024-01-13
±³À°ÀÏÀÚ : 2024-01-13
±³À°Àå¼Ò : °¡Å縯´ëÇб³ ¼ºÀDZ³Á¤ ¸¶¸®¾ÆȦ

±³À°ÁÖÁ¦ : Chemo-TIP Review Course 2024

ÁÖÃÖ±â°ü : ´ëÇѺÎÀÎÁ¾¾çÇÐȸ
´ã´çÀÚ : ÀÌÀº¿µ
¿¬¶ôó : 02-512-5915  

À̸ÞÀÏ : office@sgo.or.kr

±³À°Á¾·ù : »êºÎÀΰú

Âü¼®¿¹»óÀÎ : 150¸í
Èñ¸ÁÆòÁ¡ : 6Á¡

Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 7 ½Ã°£ 10ºÐ

¼¼ºÎ¼ö°­·á : 80,000¿ø  

ºñ°í Àü¹®ÀÇ 80,000 ¿ø / Àü°øÀÇ 60,000 ¿ø / ¿¬±¸¿ø°£È£»ç 40,000 ¿ø / ¸¸ 65¼¼ÀÌ»ó, Ã⿬Áø ¹«·á


±¸ºÐ ¿ùÀÏ °­ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ

±³À°½Ã°£ 01¿ù 13ÀÏ ¸¶¸®¾ÆȦ 09:00~09:20 Conventional cytotoxics and targeted agents ±è¼¼ÀÍ(¼­¿ïÀÇ´ë)

±³À°½Ã°£ 01¿ù 13ÀÏ ¸¶¸®¾ÆȦ 09:20~09:35 PARP inhibitors ¿À¿µÅÃ(°í·ÁÀÇ´ë)

±³À°½Ã°£ 01¿ù 13ÀÏ ¸¶¸®¾ÆȦ 09:35~09:50 Immuno-oncologics À¯Áö±Ù(°¡Å縯ÀÇ´ë)

±³À°½Ã°£ 01¿ù 13ÀÏ ¸¶¸®¾ÆȦ 09:50~10:05 Broadening the indications ¹ÚÁ¤¿­(¿ï»êÀÇ´ë)

Åä·Ð 01¿ù 13ÀÏ ¸¶¸®¾ÆȦ 10:05~10:20 Q&A ( )

±³À°½Ã°£ 01¿ù 13ÀÏ ¸¶¸®¾ÆȦ 10:20~10:40 RECIST criteria version 1.1 ¹Ú¼ººó(Áß¾ÓÀÇ´ë)

±³À°½Ã°£ 01¿ù 13ÀÏ ¸¶¸®¾ÆȦ 10:40~11:00 Case review: tumor evaluation ÃÖ¹Îö(Â÷ÀÇ´ë)

±³À°½Ã°£ 01¿ù 13ÀÏ ¸¶¸®¾ÆȦ 11:00~11:15 Q&A ( )

ÈÞ½Ä 01¿ù 13ÀÏ ¸¶¸®¾ÆȦ 11:15~11:35 Coffee break ( )

±³À°½Ã°£ 01¿ù 13ÀÏ ¸¶¸®¾ÆȦ 11:35~11:55 Ç×¾Ï °ø°í¾È (2022.8.1 °³Á¤) ÀÓÇöÁö(¼­¿ïÀÇ´ë)

±³À°½Ã°£ 01¿ù 13ÀÏ ¸¶¸®¾ÆȦ 11:55~12:10 ½ÇÁ¦ º¸Çè½É»ç »ç·Ê ¹× ÁÖÀÇ»çÇ× ±è»óÈñ(¼º±Õ°üÀÇ´ë)

Åä·Ð 01¿ù 13ÀÏ ¸¶¸®¾ÆȦ 12:10~12:20 Q&A ( )

±³À°½Ã°£ 01¿ù 13ÀÏ ¸¶¸®¾ÆȦ 12:20~12:40 Prevention of herpes zoster in gynecologic cancer patients ±¸À¯Áø(¿µ³²ÀÇ´ë)

½Ä»ç 01¿ù 13ÀÏ ¸¶¸®¾ÆȦ 12:40~13:20 Lunch ( )

±³À°½Ã°£ 01¿ù 13ÀÏ ¸¶¸®¾ÆȦ 13:20~13:35 Chemotherapy-induced nausea and vomiting Á¶¾ÈÁ©¶ó(Á¦ÁÖÀÇ´ë)

±³À°½Ã°£ 01¿ù 13ÀÏ ¸¶¸®¾ÆȦ 13:35~13:50 Cancer-related fatigue ¹Ú¼öÁø(¼­¿ïÀÇ´ë)

±³À°½Ã°£ 01¿ù 13ÀÏ ¸¶¸®¾ÆȦ 13:50~14:05 Chemotherapy-induced peripheral neuropathy ÀÌ¿ëÀç(¿¬¼¼ÀÇ´ë)

±³À°½Ã°£ 01¿ù 13ÀÏ ¸¶¸®¾ÆȦ 14:05~14:20 Hematologic toxicity ±è½ÂÈ£(ÇѸ²ÀÇ´ë)

±³À°½Ã°£ 01¿ù 13ÀÏ ¸¶¸®¾ÆȦ 14:20~14:35 Non-hematologic toxicity & hypersensitivity ¼ÕÁÖÇõ(¾ÆÁÖÀÇ´ë)

Åä·Ð 01¿ù 13ÀÏ ¸¶¸®¾ÆȦ 14:35~14:55 Q&A ( )

±³À°½Ã°£ 01¿ù 13ÀÏ ¸¶¸®¾ÆȦ 14:55~15:15 Management of immunotherapy-related toxicities ÃÖöÈÆ(¼º±Õ°üÀÇ´ë)

±³À°½Ã°£ 01¿ù 13ÀÏ ¸¶¸®¾ÆȦ 15:15~15:40 Case review: adverse effect of I/O drug ÀÌÁ¤À±(¿¬¼¼ÀÇ´ë)

Åä·Ð 01¿ù 13ÀÏ ¸¶¸®¾ÆȦ 15:40~16:00 Q&A ( )

ÈÞ½Ä 01¿ù 13ÀÏ ¸¶¸®¾ÆȦ 16:00~16:20 Coffee break ( )

±³À°½Ã°£ 01¿ù 13ÀÏ ¸¶¸®¾ÆȦ 16:20~16:40 Epithelial ovarian cancer Á¶Çö¿õ(°í·ÁÀÇ´ë)

±³À°½Ã°£ 01¿ù 13ÀÏ ¸¶¸®¾ÆȦ 16:40~17:00 Uterine cancer ³ëÁØÈ£(¼º±Õ°üÀÇ´ë)

±³À°½Ã°£ 01¿ù 13ÀÏ ¸¶¸®¾ÆȦ 17:00~17:20 Cervical cancer °­¿ÁÁÖ(¿ï»êÀÇ´ë)

Åä·Ð 01¿ù 13ÀÏ ¸¶¸®¾ÆȦ 17:20~17:30 ¡Ú Prize Draw ¡Ú ³ëÁØÈ£(¼º±Õ°üÀÇ´ë)

 

  • ÃßõÇϱâ
Tip. ±³À°ÀÏÁ¤Àº ±³À°±â°üÀÇ »çÁ¤¿¡ µû¶ó º¯°æµÉ ¼ö ÀÖÀ¸¹Ç·Î »çÀü¿¡ ¹Ýµå½Ã ±³À°±â°üÀ¸·Î ¹®ÀÇÇÏ¿© È®ÀÎ ¹Ù¶ø´Ï´Ù.
¡å
ÀÛ¼ºÀÚ   ºñ¹Ð¹øÈ£
 
¿¬¼ö°­Á ÁÖ°£º£½ºÆ®
Á¦¸ñ

[¼­¿ï] 2024 ½ÉÀå»öÀü¿¬±¸È¸ ½ÉÆ÷Áö¿ò : 2024-03-30

±³À°ÀÏÀÚ : 2024-03-30 ±³À°Àå¼Ò : »ï¼º¼­¿ïº´¿ø ÀÏ¿ø¿ª»ç Bµ¿ 9Ãþ È÷Æ÷Å©¶óÅ×½ºÈ¦ ±³À°ÁÖÁ¦ : 2024 ½ÉÀå»öÀü¿¬±¸È¸ ½ÉÆ÷Áö¿òÁÖÃÖ±â°ü : ´ëÇѳúÁ¹ÁßÇÐȸ ½ÃÇà±â°ü(ÁöºÎ/

Ãßõ¼ö : 0 , Á¶È¸¼ö : 1,206 , ´ñ±Û¼ö : 0

[ºÎ»ê] ´ëÇÑ°ñÀýÇÐȸ Á¦50Â÷ Çмú´ëȸ(1ÀÏÂ÷) : 2024-04-26

±³À°ÀÏÀÚ : 2024-04-26 ±³À°Àå¼Ò : ·Ôµ¥È£ÅÚ ºÎ»ê ±³À°ÁÖÁ¦ : ´ëÇÑ°ñÀýÇÐȸ Á¦50Â÷ Çмú´ëȸ(1ÀÏÂ÷)ÁÖÃÖ±â°ü : ´ëÇÑ°ñÀýÇÐȸ ´ã´çÀÚ : Á¤À¯Áø ¿¬¶ôó : 031-551

Ãßõ¼ö : 0 , Á¶È¸¼ö : 1,011 , ´ñ±Û¼ö : 0

[ºÎ»ê] 2024 ºÎ»ê¿ï»ê°æ³²Ä¡¸ÅÇÐȸ Ãá°èÇмú´ëȸ : 2024-03-16

±³À°ÀÏÀÚ : 2024-03-16 ±³À°Àå¼Ò : ÇØ¿î´ë¹éº´¿ø 5Ãþ ´ë°­´ç ±³À°ÁÖÁ¦ : 2024 ºÎ»ê¿ï»ê°æ³²Ä¡¸ÅÇÐȸ Ãá°èÇмú´ëȸÁÖÃÖ±â°ü : ´ëÇÑÄ¡¸ÅÇÐȸ ½ÃÇà±â°ü(ÁöºÎ/°ú) : ºÎ»ê¿ï

Ãßõ¼ö : 0 , Á¶È¸¼ö : 1,210 , ´ñ±Û¼ö : 0

[ºÎ»ê] 2024 ´ëÇѼÒÈ­±â³»½Ã°æÇÐȸ ºÎ¿ï°æÁöȸ Áú°ü¸® ½ÉÆ÷Áö¿ò : 2024-03-30

±³À°ÀÏÀÚ : 2024-03-30 ±³À°Àå¼Ò : ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ BPEX 5Ãþ ÄÁÆÛ·±½ºÈ¦ ±³À°ÁÖÁ¦ : 2024 ´ëÇѼÒÈ­±â³»½Ã°æÇÐȸ ºÎ¿ï°æÁöȸ Áú°ü¸® ½ÉÆ÷Áö¿òÁÖÃÖ±â°ü : ´ëÇÑ

Ãßõ¼ö : 0 , Á¶È¸¼ö : 1,214 , ´ñ±Û¼ö : 0

[´ë±¸] Á¦27Â÷ ´ëÇѽÉÀåÇÐȸ ´ë±¸°æºÏÁöȸ ÀÓ»ó½ÉÀåÇÐ ¿¬¼ö°­Á : 2024-03-24

±³À°ÀÏÀÚ : 2024-03-24 ±³À°Àå¼Ò : ´ë±¸ ÀÎÅÍºÒ°í ¸¸Ã̵¿ ÄÁº¥¼ÇȦ 2Ãþ ±³À°ÁÖÁ¦ : Á¦27Â÷ ´ëÇѽÉÀåÇÐȸ ´ë±¸°æºÏÁöȸ ÀÓ»ó½ÉÀåÇÐ ¿¬¼ö°­ÁÂÁÖÃÖ±â°ü : ´ëÇѽÉÀåÇÐȸ ½ÃÇà±â

Ãßõ¼ö : 0 , Á¶È¸¼ö : 1,251 , ´ñ±Û¼ö : 0